Abstract
As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic expands, genomic epidemiology and whole genome sequencing are being constantly used to investigate its transmissions and evolution. In the backdrop of the global emergence of “variants of concern” (VOCs) during December 2020 and an upsurge in a state in the western part of India since January 2021, whole genome sequencing and analysis of spike protein mutations using sequence and structural approaches was undertaken to identify possible new variants and gauge the fitness of current circulating strains.
Phylogenetic analysis revealed that the predominant clade in circulation was a distinct newly identified lineage B.1.617 possessing common signature mutations D111D, G142D, L452R, E484Q, D614G and P681R, in the spike protein including within the receptor binding domain (RBD). Of these, the mutations at residue positions 452, 484 and 681 have been reported in other globally circulating lineages. The structural analysis of RBD mutations L452R and E484Q along with P681R in the furin cleavage site, may possibly result in increased ACE2 binding and rate of S1-S2 cleavage resulting in better transmissibility. The same two RBD mutations indicated decreased binding to selected monoclonal antibodies (mAbs) and may affect their neutralization potential. Experimental validation is warranted for accessing both ACE2 binding and the effectiveness of commonly elicited neutralizing mAbs for the strains of lineage B.1.617.
The emergence of such local variants through the accumulation of convergent mutations during the COVID-19 second wave needs to be further investigated for their public health impact in the rest of the country and its possibility of becoming a VOC.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
↵@ Sucheta Patil, Prachi Jagtap, Bhagyashri Kasabe, Ujjaini Shah, Trupti Sanjeev, Gayatri Divekar, Kalpita Korabu, Sunil Shelkande, Pooja Shinde, Sayed Zakiuddin, Veena Vipat, Sheetal Jadhav, Krutika Iyengar, Vinita Malik, Sonali Bhorekar, Abhinendra Kumar, Rima Sahay, Anita Shete, M.L.Choudhary from National Influenza Center (NIC)
↵$ DBT-Institute of Life Sciences (ILS), Bhubaneswar, DBT-National Centre for Cell Science, (NCCS) Pune, CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, DBT-Centre for DNA Fingerprinting and Diagnosis (CDFD), Hyderabad, DBT- The Institute for Stem Cell Science and Regenerative Medicine (InSTEM), Bengaluru, National Centre for Biological Sciences (NCBS), Bengaluru, National Institute of Mental Health and Neuro-Sciences (NIMHANS), Bengaluru, Trivedi School of Biosciences, Ashoka University, New Delhi